Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
Abstract Purpose We aimed to evaluate the efficacy and safety of 28‐day Cyclic and 84‐day Extended regimens of NPC‐16 (ethinylestradiol 0.02 mg plus levonorgestrel 0.09 mg) in patients with dysmenorrhea. Methods This was a placebo‐controlled, double‐blind, randomized trial conducted in Japan. A tota...
Main Authors: | Tasuku Harada, Mikio Momoeda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Reproductive Medicine and Biology |
Subjects: | |
Online Access: | https://doi.org/10.1002/rmb2.12373 |
Similar Items
-
Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study
by: Momoeda M, et al.
Published: (2020-05-01) -
Ethinylestradiol and Levonorgestrel as Active Agents in Normal Skin, and Pathological Conditions Induced by UVB Exposure: In Vitro and In Ovo Assessments
by: Dorina Coricovac, et al.
Published: (2018-11-01) -
Oral ethinylestradiol–levonorgestrel therapy counteracts fructose-induced renal metabolic impairment in female rats
by: Kehinde Samuel Olaniyi, et al.
Published: (2021-09-01) -
Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study
by: Momoeda M, et al.
Published: (2017-05-01) -
Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study
by: Momoeda M, et al.
Published: (2020-03-01)